These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33339442)

  • 1. Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
    Wada M; Kukita A; Sone K; Hamamoto R; Kaneko S; Komatsu M; Takahashi Y; Inoue F; Kojima M; Honjoh H; Taguchi A; Kashiyama T; Miyamoto Y; Tanikawa M; Tsuruga T; Mori-Uchino M; Wada-Hiraike O; Osuga Y; Fujii T
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33339442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
    Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
    Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
    Veschi V; Liu Z; Voss TC; Ozbun L; Gryder B; Yan C; Hu Y; Ma A; Jin J; Mazur SJ; Lam N; Souza BK; Giannini G; Hager GL; Arrowsmith CH; Khan J; Appella E; Thiele CJ
    Cancer Cell; 2017 Jan; 31(1):50-63. PubMed ID: 28073004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
    Ma A; Yu W; Li F; Bleich RM; Herold JM; Butler KV; Norris JL; Korboukh V; Tripathy A; Janzen WP; Arrowsmith CH; Frye SV; Vedadi M; Brown PJ; Jin J
    J Med Chem; 2014 Aug; 57(15):6822-33. PubMed ID: 25032507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
    Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
    Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCC.
    Li X; Liu Z; Xia C; Yan K; Fang Z; Fan Y
    Cancer Lett; 2022 Feb; 527():150-163. PubMed ID: 34942305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer Cells.
    Kukita A; Sone K; Kaneko S; Kawakami E; Oki S; Kojima M; Wada M; Toyohara Y; Takahashi Y; Inoue F; Tanimoto S; Taguchi A; Fukuda T; Miyamoto Y; Tanikawa M; Mori-Uchino M; Tsuruga T; Iriyama T; Matsumoto Y; Nagasaka K; Wada-Hiraike O; Oda K; Hamamoto R; Osuga Y
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SETD8 inhibits apoptosis and ferroptosis of Ewing's sarcoma through YBX1/RAC3 axis.
    Chen H; Hu J; Xiong X; Chen H; Liao Q; Lin B; Chen Y; Peng Y; Li Y; Cheng D; Li Z
    Cell Death Dis; 2024 Jul; 15(7):494. PubMed ID: 38987564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
    Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
    BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer.
    Liu M; Qin Y; Hu Q; Liu W; Ji S; Xu W; Fan G; Ye Z; Zhang Z; Xu X; Yu X; Zhuo Q
    Cancer Lett; 2021 Feb; 499():265-278. PubMed ID: 33232789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.
    Takawa M; Cho HS; Hayami S; Toyokawa G; Kogure M; Yamane Y; Iwai Y; Maejima K; Ueda K; Masuda A; Dohmae N; Field HI; Tsunoda T; Kobayashi T; Akasu T; Sugiyama M; Ohnuma S; Atomi Y; Ponder BA; Nakamura Y; Hamamoto R
    Cancer Res; 2012 Jul; 72(13):3217-27. PubMed ID: 22556262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Determinants of Erythropoiesis: Role of the Histone Methyltransferase SetD8 in Promoting Erythroid Cell Maturation and Survival.
    DeVilbiss AW; Sanalkumar R; Hall BD; Katsumura KR; de Andrade IF; Bresnick EH
    Mol Cell Biol; 2015 Jun; 35(12):2073-87. PubMed ID: 25855754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SETD8 promotes stemness characteristics and is a potential prognostic biomarker of gastric adenocarcinoma.
    Piao L; Che N; Li H; Li M; Feng Y; Liu X; Kim S; Jin Y; Xuan Y
    Exp Mol Pathol; 2020 Dec; 117():104560. PubMed ID: 33127342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PPARγ-SETD8 axis constitutes an epigenetic, p53-independent checkpoint on p21-mediated cellular senescence.
    Shih CT; Chang YF; Chen YT; Ma CP; Chen HW; Yang CC; Lu JC; Tsai YS; Chen HC; Tan BC
    Aging Cell; 2017 Aug; 16(4):797-813. PubMed ID: 28514051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship studies of SETD8 inhibitors.
    Ma A; Yu W; Xiong Y; Butler KV; Brown PJ; Jin J
    Medchemcomm; 2014 Dec; 5(12):1892-1898. PubMed ID: 25554733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SETD8 involved in the progression of inflammatory bowel disease via epigenetically regulating p62 expression.
    Chen P; Zhu H; Mao Y; Zhuo M; Yu Y; Chen M; Zhao Q; Li L; Wu M; Ye M
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2850-2863. PubMed ID: 33991018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha heterodimer targets the histone modification enzyme PR-Set7/Setd8 gene and regulates adipogenesis through a positive feedback loop.
    Wakabayashi K; Okamura M; Tsutsumi S; Nishikawa NS; Tanaka T; Sakakibara I; Kitakami J; Ihara S; Hashimoto Y; Hamakubo T; Kodama T; Aburatani H; Sakai J
    Mol Cell Biol; 2009 Jul; 29(13):3544-55. PubMed ID: 19414603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. USP29 Deubiquitinates SETD8 and Regulates DNA Damage-Induced H4K20 Monomethylation and 53BP1 Focus Formation.
    Hernández-Reyes Y; Paz-Cabrera MC; Freire R; Smits VAJ
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
    El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
    Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.